1. Overview
Factor VIII, also known as the antihemophilic factor, is a critical protein involved in the blood coagulation process. It plays a central role in the intrinsic pathway of the coagulation cascade and is essential for effective clot formation following vascular injury. Factor VIII is encoded by the F8 gene, and defects in this gene result in Hemophilia A, an X-linked bleeding disorder.
Factor VIII is also deficient or dysfunctional in patients with von Willebrand disease. In addition to its role in bleeding disorders, elevated Factor VIII levels have been identified as an independent risk factor for venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism, particularly in cancer patients. Factor VIII–related antigen is widely used in immunohistochemistry (IHC) as a marker of endothelial cells.
2. Symptoms
Clinical manifestations associated with Factor VIII abnormalities depend on whether activity levels are reduced or elevated. Reduced Factor VIII activity leads to bleeding tendencies characteristic of Hemophilia A. These may include prolonged bleeding after injury or surgery, spontaneous bleeding episodes, easy bruising, and bleeding into joints or soft tissues in severe cases.
The severity of symptoms correlates with the degree of Factor VIII deficiency, with severe deficiency causing frequent spontaneous bleeding and mild deficiency resulting in bleeding mainly after trauma or surgical procedures.
3. Causes
Factor VIII deficiency is most commonly caused by inherited mutations in the F8 gene, leading to Hemophilia A. This condition follows an X-linked inheritance pattern and is significantly more common than Hemophilia B.
Abnormally low Factor VIII activity may also be seen in acquired conditions such as von Willebrand disease, acquired Factor VIII inhibitors, liver disease, disseminated intravascular coagulation (DIC), vitamin K deficiency, autoimmune disorders with Factor VIII antibodies, combined Factor V and VIII deficiency, severe malnutrition, and critical illness.
Conversely, elevated Factor VIII levels may occur in inflammatory states, malignancies, and conditions associated with endothelial activation.
4. Risk Factors
Risk factors for Factor VIII–related disorders include a family history of Hemophilia A, carrier status in female relatives, unexplained bleeding disorders, and abnormal coagulation profile results.
Low Factor VIII activity is associated with increased bleeding risk, while elevated levels increase the risk of thrombotic events such as deep venous thrombosis and pulmonary embolism. Age-related variations are noted, with older adults tending to have higher Factor VIII levels.
The severity of Hemophilia A is classified based on Factor VIII activity levels: severe (<1%), moderate (1–5%), and mild (5–40%).
5. Prevention and Clinical Management
Clinical management of Factor VIII abnormalities relies on accurate laboratory assessment, appropriate patient preparation, and targeted therapy. Indications for testing include suspected Hemophilia A, unexplained bleeding disorders, carrier testing, preoperative assessment, prenatal diagnosis, and abnormal coagulation profiles.
Patients are advised to discontinue warfarin at least two weeks before testing and avoid direct Xa inhibitors, heparin, and thrombin inhibitors at least three days before sample collection. Blood samples should not be drawn from heparinized catheters. Citrate plasma is used for coagulation assays, with strict protocols for collection, processing, storage, and transport.
Factor VIII activity is commonly measured using two-stage assays, where patient plasma is analyzed for its ability to generate Factor Xa and support clot formation. Normal activity levels range from 50% to 150% of laboratory reference values.
In immunohistochemistry, Factor VIII antigen demonstrates cytoplasmic staining, with endothelium serving as a positive internal control. IHC is useful in evaluating vascular tumors, endothelial activation, and the severity of Factor VIII deficiency.
Diagnostic utility includes confirming Hemophilia A, monitoring replacement therapy, detecting inhibitors, assessing bleeding risk, guiding perioperative management, and supporting genetic counseling. Prognosis is closely linked to disease severity, inhibitor status, and response to therapy, with management strategies tailored accordingly.
